Logo image of ANEB

ANEBULO PHARMACEUTICALS INC (ANEB) Stock Fundamental Analysis

USA - NASDAQ:ANEB - US0345691036 - Common Stock

2.69 USD
-0.01 (-0.37%)
Last: 10/28/2025, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ANEB. ANEB was compared to 192 industry peers in the Pharmaceuticals industry. ANEB has a great financial health rating, but its profitability evaluates not so good. ANEB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ANEB had negative earnings in the past year.
In the past year ANEB has reported a negative cash flow from operations.
In the past 5 years ANEB always reported negative net income.
In the past 5 years ANEB always reported negative operating cash flow.
ANEB Yearly Net Income VS EBIT VS OCF VS FCFANEB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

ANEB's Return On Assets of -69.86% is on the low side compared to the rest of the industry. ANEB is outperformed by 68.23% of its industry peers.
With a Return On Equity value of -72.78%, ANEB perfoms like the industry average, outperforming 46.88% of the companies in the same industry.
Industry RankSector Rank
ROA -69.86%
ROE -72.78%
ROIC N/A
ROA(3y)-123.91%
ROA(5y)-118.64%
ROE(3y)-132.86%
ROE(5y)-124.7%
ROIC(3y)N/A
ROIC(5y)N/A
ANEB Yearly ROA, ROE, ROICANEB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANEB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANEB Yearly Profit, Operating, Gross MarginsANEB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANEB has more shares outstanding
ANEB has more shares outstanding than it did 5 years ago.
ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANEB Yearly Shares OutstandingANEB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ANEB Yearly Total Debt VS Total AssetsANEB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

ANEB has an Altman-Z score of 126.57. This indicates that ANEB is financially healthy and has little risk of bankruptcy at the moment.
ANEB's Altman-Z score of 126.57 is amongst the best of the industry. ANEB outperforms 99.48% of its industry peers.
ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 126.57
ROIC/WACCN/A
WACCN/A
ANEB Yearly LT Debt VS Equity VS FCFANEB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 10M 20M

2.3 Liquidity

ANEB has a Current Ratio of 24.53. This indicates that ANEB is financially healthy and has no problem in meeting its short term obligations.
ANEB's Current ratio of 24.53 is amongst the best of the industry. ANEB outperforms 94.79% of its industry peers.
ANEB has a Quick Ratio of 24.53. This indicates that ANEB is financially healthy and has no problem in meeting its short term obligations.
ANEB has a better Quick ratio (24.53) than 95.31% of its industry peers.
Industry RankSector Rank
Current Ratio 24.53
Quick Ratio 24.53
ANEB Yearly Current Assets VS Current LiabilitesANEB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

ANEB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.75%, which is quite good.
EPS 1Y (TTM)18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 65.24% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-88.31%
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%
EPS Next 5Y65.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANEB Yearly Revenue VS EstimatesANEB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2031 2032 20M 40M 60M 80M
ANEB Yearly EPS VS EstimatesANEB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANEB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANEB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANEB Price Earnings VS Forward Price EarningsANEB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANEB Per share dataANEB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

ANEB's earnings are expected to decrease with -24.34% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%

More info and screens

0

5. Dividend

5.1 Amount

ANEB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANEBULO PHARMACEUTICALS INC

NASDAQ:ANEB (10/28/2025, 8:00:00 PM)

2.69

-0.01 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-29 2025-09-29/amc
Earnings (Next)11-07 2025-11-07
Inst Owners54.99%
Inst Owner Change-1.55%
Ins Owners40.54%
Ins Owner Change0%
Market Cap110.51M
Revenue(TTM)N/A
Net Income(TTM)-8484700
Analysts43.33
Price Target8.16 (203.35%)
Short Float %0.75%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.15%
Min EPS beat(2)21.57%
Max EPS beat(2)38.73%
EPS beat(4)2
Avg EPS beat(4)-1.72%
Min EPS beat(4)-56.86%
Max EPS beat(4)38.73%
EPS beat(8)5
Avg EPS beat(8)14.23%
EPS beat(12)7
Avg EPS beat(12)10.01%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)45.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.48
P/tB 9.48
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.86%
ROE -72.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.91%
ROA(5y)-118.64%
ROE(3y)-132.86%
ROE(5y)-124.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 24.53
Quick Ratio 24.53
Altman-Z 126.57
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-88.31%
EPS Next 2Y-34.34%
EPS Next 3Y-24.34%
EPS Next 5Y65.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.52%
OCF growth 3YN/A
OCF growth 5YN/A

ANEBULO PHARMACEUTICALS INC / ANEB FAQ

Can you provide the ChartMill fundamental rating for ANEBULO PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ANEB.


What is the valuation status of ANEBULO PHARMACEUTICALS INC (ANEB) stock?

ChartMill assigns a valuation rating of 0 / 10 to ANEBULO PHARMACEUTICALS INC (ANEB). This can be considered as Overvalued.


How profitable is ANEBULO PHARMACEUTICALS INC (ANEB) stock?

ANEBULO PHARMACEUTICALS INC (ANEB) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ANEB stock?

The Earnings per Share (EPS) of ANEBULO PHARMACEUTICALS INC (ANEB) is expected to decline by -88.31% in the next year.